An Open Label, Phase II, Multicenter Study to Evaluate the Efficacy and Safety of a Recombinant Humanized Antibody to HER2 (Pertuzumab) Administered Every 3 Weeks to Patients With Hormone-Refractory Prostate Cancer Who Have Not Been Treated With Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 31 May 2017
At a glance
- Drugs Pertuzumab (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Sponsors Roche
- 31 Aug 2018 Biomarkers information updated
- 17 Sep 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche website.